Dr Neeraj Agarwal on PARP Inhibitor Combination Treatments for Prostate Cancer
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses promising investigational combinations including PARP inhibitors in the treatment of prostate cancer.
Transcript
PARP inhibitors are being studied in combination with other therapies—which regimens being studied do you believe hold the most promise in prostate cancer?
I think the combination of PARP inhibitors with novel hormonal therapy definitely has promise. So whether it’s a combination of talazoparib with enzalutamide as being tested in
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- The Impact of ADT for Prostate Cancer on Survival and Patient Well-Being
February 14th 2025